RT Journal Article SR Electronic T1 11C-Acetate PET Imaging of Prostate Cancer JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 181 OP 186 VO 43 IS 2 A1 Nobuyuki Oyama A1 Hironobu Akino A1 Hiroshi Kanamaru A1 Yuji Suzuki A1 Satoshi Muramoto A1 Yoshiharu Yonekura A1 Norihiro Sadato A1 Kazutaka Yamamoto A1 Kenichiro Okada YR 2002 UL http://jnm.snmjournals.org/content/43/2/181.abstract AB 11C-Acetate can act as a probe of tissue metabolism through entry into catabolic or anabolic metabolic pathways as mediated by acetyl–coenzyme A. The uptake of 11C-acetate in prostate cancer was investigated to determine whether this tracer has potential in tumor identification. Methods: Twenty-two patients with prostate cancer underwent PET after intravenous administration of 740 MBq 11C-acetate. Eighteen of the 22 patients were also investigated with 18F-FDG PET. Standardized uptake values (SUVs) for each tumor were investigated for tracer activity at 10–20 min after 11C-acetate and 40–60 min after 18F-FDG administration. Results: Adenocarcinoma of the prostate showed variable uptake of 11C-acetate, with SUVs ranging from 3.27 to 9.87. In contrast, SUVs for 18F-FDG ranged from 1.97 to 6.34. By visual inspection, 11C-acetate accumulation in primary prostate tumors was positive in all patients, whereas 18F-FDG accumulation was positive in only 15 of 18 patients. 11C-Acetate PET in a patient with lymph node metastasis showed high intrapelvic accumulation corresponding to metastatic sites. Similarly, 2 patients with bone metastases were 11C-acetate avid. Conclusion: 11C-Acetate shows marked uptake in prostate cancer and is more sensitive in detection of prostate cancer than is 18F-FDG PET. 11C-Acetate represents a new tracer for detection of prostate cancer with PET, measuring radiopharmaceutical uptake pathways that are different from those measured by 18F-FDG.